Neurology Section, Department of Medicine, King Abdulaziz Medical City, Jeddah, Saudi Arabia; King Abdullah International Medical Research Center, Jeddah, Saudi Arabia; College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia.
Department of Neuroscience, King Faisal Specialist Hospital and Research Centre, Jeddah, Saudi Arabia.
Acta Neurol Taiwan. 2023 Jun 30;32(2):82-85.
The onset of the COVID-19 (SARS-CoV-2) pandemic in December 2019 created the need for multiple scientific research activities and clinical trials in an attempt to find solutions to mitigate the impact of the virus. One of the important tools to combat the virus is the development of vaccination programs. All types of vaccines have been associated with a mild to severe risk of neurological adverse events. One of these severe adverse events is Guillain-Barré syndrome.
Here, we describe a case of Guillain-Barré syndrome after the first dose of the BNT162b2 mRNA COVID-19 vaccine and review the literature to increase the current knowledge regarding this complication.
Guillain-Barré syndrome after COVID-19 vaccination is responsive to treatment. The benefits of administering the vaccine outweigh the risks. Due to the negative impact of COVID-19, it is essential to recognize the development of neurological complications that are potentially associated with vaccination, including Guillain-Barré syndrome.
2019 年 12 月，COVID-19（SARS-CoV-2）大流行的爆发催生了多项科学研究活动和临床试验，试图寻找减轻病毒影响的解决方案。对抗病毒的重要手段之一是开发疫苗接种计划。所有类型的疫苗都与轻度至重度的神经不良事件风险相关。其中一种严重的不良事件是吉兰-巴雷综合征。
在这里，我们描述了一例首例 BNT162b2 mRNA COVID-19 疫苗接种后发生的吉兰-巴雷综合征病例，并回顾了文献，以增加对该并发症的现有认识。
COVID-19 疫苗接种后发生的吉兰-巴雷综合征对治疗有反应。接种疫苗的益处大于风险。由于 COVID-19 的负面影响，必须认识到与接种相关的潜在神经并发症的发生，包括吉兰-巴雷综合征。
